Welcome to our dedicated page for ProAssurance news (Ticker: PRA), a resource for investors and traders seeking the latest updates and insights on ProAssurance stock.
ProAssurance Corporation reports developments tied to its property and casualty insurance holding company operations. Its insurance subsidiaries provide professional liability coverage for healthcare professionals and facilities, professional liability coverage for attorneys, and workers' compensation insurance.
Company news commonly covers operating and financial results, investment portfolio updates, capital-structure disclosures, governance matters, and segment-level activity across Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, and Corporate reporting areas.
The Doctors Company has completed its acquisition of ProAssurance (NYSE: PRA), a specialty medical liability and workers' compensation insurer, for $25.00 per share in cash, valuing the deal at about $1.3 billion.
The combined company will protect over 200,000 healthcare professionals and organizations and hold $12 billion in assets. ProAssurance will be deregistered with the SEC, delisted from the NYSE, and operated as a wholly owned subsidiary while its optimal structure is reviewed.
NETSTREIT (NYSE: NTST) will join the S&P SmallCap 600, replacing ProAssurance (NYSE: PRA), effective before the market opens on June 29, 2026. The change follows a pending cash acquisition of ProAssurance by The Doctors Company, subject to final closing conditions.
ProAssurance (NYSE: PRA) reported Q1 2026 net income of $8.5 million ($0.16 diluted) and Non-GAAP operating income of $12.7 million ($0.25 diluted). Consolidated net premiums written were $258.6 million. Consolidated Non-GAAP combined ratio improved to 109.9%. Book value per share was $25.94 and Non-GAAP adjusted book value per share was $27.86. The company continues to pursue a pending transaction with The Doctors Company, anticipating closing by June 30, 2026, subject to remaining state insurance regulator approvals.
ProAssurance (NYSE: PRA) reported Q4 2025 net income $33.4M ($0.64/diluted) and operating income $42.4M ($0.82/diluted); FY 2025 net income $50.9M ($0.99) and operating income $83.9M ($1.62).
Consolidated net premiums written were $916.9M, including $673.6M for medical professional liability. Consolidated Non-GAAP combined ratio improved to 104.2% for 2025; book value per share rose to $26.24 and adjusted book value to $27.82. The company reiterated the planned transaction with The Doctors Company and continues to anticipate closing by June 30, 2026, subject to remaining regulator approvals.
Summary not available.
ProAssurance (NYSE:PRA) reported strong Q2 2025 results with net income of $21.9 million ($0.42 per diluted share) and operating income of $26.8 million ($0.52 per diluted share). The company demonstrated significant progress in its medical professional liability and workers' compensation markets.
Key highlights include stable net premiums written of $135.9 million in Medical Professional Liability business, 10% premium increases in Specialty P&C segment, and an 81% retention rate. The consolidated Non-GAAP combined ratio improved by 9.5 percentage points year-over-year. Book value per share increased to $24.80, up from $23.49 at year-end 2024.
The company's pending merger with The Doctors Company received stockholder approval and FTC clearance, with expected closing in H1 2026.
ProAssurance Corporation (NYSE: PRA) and The Doctors Company have achieved a significant milestone in their pending acquisition deal with the early termination of the Hart-Scott-Rodino waiting period by the U.S. Federal Trade Commission on July 2, 2025.
The Doctors Company, the largest physician-owned medical malpractice insurer in the U.S., is set to acquire ProAssurance, a specialty insurer focused on medical liability, medical technology products liability, and workers' compensation insurance. The transaction is expected to close in the first half of 2026, subject to remaining regulatory approvals and other customary closing conditions.
ProAssurance Corporation (NYSE: PRA) announced that stockholders have overwhelmingly approved its proposed acquisition by The Doctors Company, with over 99% of shares voting in favor. The transaction is expected to close in the first half of 2026, subject to regulatory approvals including Hart-Scott-Rodino Act requirements and state insurance regulators' approval.
Upon completion, PRA will delist from NYSE and become a wholly owned subsidiary of The Doctors Company. The merger aims to combine both companies' strengths in the medical professional liability marketplace, with no financing conditions attached.
ProAssurance (NYSE: PRA) will be acquired by The Doctors Company Insurance Group (TDC Group), as announced on March 19, 2025. The transaction is expected to close in the first half of 2026, subject to regulatory approval. Following the acquisition, PRA will be 100% owned by The Doctors Company.
AM Best has confirmed that ProAssurance's Financial Strength Rating of A (Excellent) and Long-Term Issuer Credit Ratings of 'a+' (Excellent) remain unchanged, with a stable outlook. The ratings reflect ProAssurance's strongest balance sheet strength, adequate operating performance, favorable business profile, and appropriate enterprise risk management.
The merger combines the fourth-largest medical professional liability (MPL) insurance writer (ProAssurance) with the second-largest (TDC Group) in the United States, based on direct premiums written. AM Best will continue monitoring both organizations independently during the extended transaction period.